AU2023246547A1 - 5-meo-dmt for use in the treatment of postpartum depression - Google Patents

5-meo-dmt for use in the treatment of postpartum depression Download PDF

Info

Publication number
AU2023246547A1
AU2023246547A1 AU2023246547A AU2023246547A AU2023246547A1 AU 2023246547 A1 AU2023246547 A1 AU 2023246547A1 AU 2023246547 A AU2023246547 A AU 2023246547A AU 2023246547 A AU2023246547 A AU 2023246547A AU 2023246547 A1 AU2023246547 A1 AU 2023246547A1
Authority
AU
Australia
Prior art keywords
dmt
meo
pharmaceutically acceptable
acceptable salt
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023246547A
Other languages
English (en)
Inventor
Conor Burke
Naoise GAFFNEY
Theis Terwey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GH Research Ireland Ltd
Original Assignee
GH Research Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GH Research Ireland Ltd filed Critical GH Research Ireland Ltd
Priority claimed from PCT/EP2023/057873 external-priority patent/WO2023186826A1/en
Publication of AU2023246547A1 publication Critical patent/AU2023246547A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023246547A 2022-03-27 2023-03-27 5-meo-dmt for use in the treatment of postpartum depression Pending AU2023246547A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22000083.0 2022-03-27
EP22000086 2022-03-27
EP22000086.3 2022-03-27
EP22000083 2022-03-27
EP23153995.8 2023-01-30
EP23153939 2023-01-30
EP23153995 2023-01-30
EP23153939.6 2023-01-30
PCT/EP2023/057873 WO2023186826A1 (en) 2022-03-27 2023-03-27 5-meo-dmt for use in the treatment of postpartum depression

Publications (1)

Publication Number Publication Date
AU2023246547A1 true AU2023246547A1 (en) 2024-11-07

Family

ID=93294635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023246547A Pending AU2023246547A1 (en) 2022-03-27 2023-03-27 5-meo-dmt for use in the treatment of postpartum depression

Country Status (7)

Country Link
US (1) US20250221963A1 (https=)
EP (1) EP4499079A1 (https=)
JP (1) JP2025511072A (https=)
KR (1) KR20240167885A (https=)
AU (1) AU2023246547A1 (https=)
CA (1) CA3255644A1 (https=)
IL (1) IL315893A (https=)

Also Published As

Publication number Publication date
JP2025511072A (ja) 2025-04-15
CA3255644A1 (en) 2023-10-05
US20250221963A1 (en) 2025-07-10
EP4499079A1 (en) 2025-02-05
IL315893A (en) 2024-11-01
KR20240167885A (ko) 2024-11-28

Similar Documents

Publication Publication Date Title
WO2023186826A1 (en) 5-meo-dmt for use in the treatment of postpartum depression
WO2023186827A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
AU2023426967A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
WO2024160392A1 (en) 5-meo-dmt for use in the treatment of postpartum depression
AU2023246547A1 (en) 5-meo-dmt for use in the treatment of postpartum depression
AU2023242438A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
CN118946354A (zh) 用于治疗产后抑郁的5-MeO-DMT
EP4499086A1 (en) Treatment of mental disorders
CN118973569A (zh) 用于治疗双相情感障碍的5-甲氧基-n,n-二甲基色胺